Oxford Biomedical Research Centre Signs Contract With GENALICE for its Breakthrough Sequenced DNA Data Processing Solution - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Oxford Biomedical Research Centre Signs Contract With GENALICE for its Breakthrough Sequenced DNA Data Processing Solution


Oxford Biomedical Research Centre Signs Contract With GENALICE for its Breakthrough Sequenced DNA Data Processing Solution

PR Newswire

HARDERWIJK, the Netherlands, June 17, 2014 /PRNewswire/ --

GENALICE today announced that the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre's Molecular Diagnostics Centre has signed a contract for a larger model of the GENALICE VAULT, GENALICE's Next-Generation Sequencing (NGS) data processing appliance. This all-in-one bioinformatics appliance is preloaded with the ultra-fast and highly accurate NGS data processing software, GENALICE MAP.

GENALICE recently announced the upgrade of its groundbreaking DNA processing solution to include Variant Calling. This upgrade makes GENALICE MAP a complete processing workflow. The product is specifically designed to support high volume DNA sequencing centers that require high throughput at high quality.

Dr. Anna Schuh, Clinical Lead at the Oxford Molecular Diagnostics Centre, comments: "GENALICE showed that MAP produces impressive throughput and storage space reductions.  It also detects complex mutations, which is crucial to be able to effectively use NGS data in a clinical setting and a key catalyst in allowing clinical use to contribute to large scale DNA data collection."

Hans Karten, CEO/CTO of GENALICE, is delighted with this agreement. He commented: "The Oxford group is world renown and uses high quality standards. This is a major milestone in our continuous product validation and quality improvement process. The team in Oxford is gearing up for a more molecular profile driven diagnosis and treatment of complex diseases. We are excited to accelerate this process."

He continued: "In order to optimally support our customers in United Kingdom and Ireland, we have opened an office in the Innovation Center in Belfast, Northern Ireland. As well as customer support, the UK office will also carry out part of the product development and validation functions within GENALICE.


GENALICE is a privately owned, innovative biomedical big data company, with headquarters in Harderwijk, the Netherlands. It designs and builds groundbreaking software solutions for cost effective and accurate DNA data processing and analysis on simple commodity hardware. Its mission is to save lives and improve the quality of life of people with complex DNA-related diseases, such as cancer. With state of the art technology GENALICE wants to make an important contribution to improved drug development, diagnosis and treatment.

The NIHR Oxford Biomedical Research Centre is a partnership between the research expertise of the Oxford University Hospitals NHS Trust and the University of Oxford. Its main aim is to enable clinical research for patient benefit and foster innovation to improve healthcare. It is funded by the National Institute for Health Research (NIHR). The NIHR provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university), and conducting leading edge research focused on the needs of patients. http://www.oxfordbrc.nihr.ac.uk

http://www.genalice.com

Twitter - YouTube - Facebook - Skype: GenaliceDNA

SOURCE GENALICE B.V.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here